![Jaap Blaak](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Jaap Blaak is the founder of VenGen BV (founded in 2001) and TAilWind BV (founded in 1995), where he holds the titles of Venture Partner and President respectively.
He also founded Piculet Biosciences BV (founded in 2004) and served as the Chairman-Supervisory Board.
Mr. Blaak is also the founder of VenGen Holding BV.
Mr. Blaak's former jobs include being a Director at FlexGen Holding BV, Janssen Biologics BV, and Pharming Group NV, where he served as an Independent Member-Supervisory Board from 2016 to 2018.
He was also a Member-Supervisory Board at to-BBB Holding BV and to-BBB technologies BV.
In terms of education, Mr. Blaak is a graduate of Vrije Universiteit Amsterdam.
Postes actifs de Jaap Blaak
| Sociétés | Poste | Début |
|---|---|---|
VenGen BV
 VenGen BV Investment ManagersFinance VenGen's investment strategy focuses on pre-seed stage ventures. They look for technologies that represent significant breakthroughs primarily in life sciences in addition to therapeutics, diagnostics, medical devices and platform technologies. They also consider ideas that have initial proof of concept such as validation via publication in peer-reviewed journals, protection through patent applications or awards of competitive grants. Among VenGen's other investment criteria are technologies or products with substantial market value which meet an unmet need and personal fit between the entrepreneur and the firm's founders. The firm provides various levels of funding. When the business concept, intellectual property, scientific basis and market potential are deemed promising, they provide an investment of EUR 10 thousand combined with entrepreneurial coaching (VenGen Support). Another stage of investment is when the business plan is defined, the spin-out process finalized and investors have been identified. At this point, VenGen invests up to EUR 50 thousand (VenGen Accell). VenGen is an active, hands-on partner. They provide business expertise and management experience in addition to initial funding. They are committed to their portfolio firm's by playing an active role. They draw on their wide network of specialized business and industry partners for the benefit of the entrepreneurs. They organize meetings with their advisory board members to discuss strategic developments and planning. VenGen also considers spin-out opportunities which are directly initiated by technology transfer officials associated with research departments of universities and life science institutes. | Fondateur | 20/07/2011 |
TAilWind BV
 TAilWind BV Financial ConglomeratesFinance Provides financial and investment services to biotechnology companies | Fondateur | 29/06/2011 |
Anciens postes connus de Jaap Blaak
| Sociétés | Poste | Fin |
|---|---|---|
| PHARMING GROUP N.V. | Président | 25/05/2016 |
VenGen Holding BV
 VenGen Holding BV Financial ConglomeratesFinance Provides investment services | Fondateur | - |
FlexGen Holding BV
 FlexGen Holding BV Medical SpecialtiesHealth Technology Produces micro-arrays with the use of lasers in the synthesis of oligonucleotides | Directeur/Membre du Conseil | - |
Janssen Biologics BV
 Janssen Biologics BV Pharmaceuticals: MajorHealth Technology Manufactures, acquires and markets biopharmaceutical therapies | Directeur/Membre du Conseil | - |
to-BBB Holding BV
 to-BBB Holding BV Pharmaceuticals: GenericHealth Technology Operates as a holding company with interests in providing central nervous system drug technology to the pharmaceutical and biotechnology industries | Directeur/Membre du Conseil | - |
Formation de Jaap Blaak
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
23
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Pharming Group NV
 Pharming Group NV Pharmaceuticals: MajorHealth Technology Develops and commercializes protein replacement therapies and precision medicines | Health Technology |
Vrije Universiteit Amsterdam
 Vrije Universiteit Amsterdam Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
VenGen BV
VenGen BV Investment ManagersFinance VenGen's investment strategy focuses on pre-seed stage ventures. They look for technologies that represent significant breakthroughs primarily in life sciences in addition to therapeutics, diagnostics, medical devices and platform technologies. They also consider ideas that have initial proof of concept such as validation via publication in peer-reviewed journals, protection through patent applications or awards of competitive grants. Among VenGen's other investment criteria are technologies or products with substantial market value which meet an unmet need and personal fit between the entrepreneur and the firm's founders. The firm provides various levels of funding. When the business concept, intellectual property, scientific basis and market potential are deemed promising, they provide an investment of EUR 10 thousand combined with entrepreneurial coaching (VenGen Support). Another stage of investment is when the business plan is defined, the spin-out process finalized and investors have been identified. At this point, VenGen invests up to EUR 50 thousand (VenGen Accell). VenGen is an active, hands-on partner. They provide business expertise and management experience in addition to initial funding. They are committed to their portfolio firm's by playing an active role. They draw on their wide network of specialized business and industry partners for the benefit of the entrepreneurs. They organize meetings with their advisory board members to discuss strategic developments and planning. VenGen also considers spin-out opportunities which are directly initiated by technology transfer officials associated with research departments of universities and life science institutes. | Finance |
to-BBB Holding BV
to-BBB Holding BV Pharmaceuticals: GenericHealth Technology Operates as a holding company with interests in providing central nervous system drug technology to the pharmaceutical and biotechnology industries | Health Technology |
to-BBB technologies BV
 to-BBB technologies BV Pharmaceuticals: MajorHealth Technology Develops medicines for brain disease treatment | Health Technology |
VenGen Holding BV
VenGen Holding BV Financial ConglomeratesFinance Provides investment services | Finance |
FlexGen Holding BV
FlexGen Holding BV Medical SpecialtiesHealth Technology Produces micro-arrays with the use of lasers in the synthesis of oligonucleotides | Health Technology |
TAilWind BV
TAilWind BV Financial ConglomeratesFinance Provides financial and investment services to biotechnology companies | Finance |
Piculet Biosciences BV
 Piculet Biosciences BV BiotechnologyHealth Technology Develops and markets oligonucleotide binding moieties for pharmaceutical applications | Health Technology |
Janssen Biologics BV
Janssen Biologics BV Pharmaceuticals: MajorHealth Technology Manufactures, acquires and markets biopharmaceutical therapies | Health Technology |
